Challenge yourself with our latest quiz covering management of AL amyloidosis in the treatment of patients with multiple myeloma.
A.Amyloid light-chain (AL) amyloidosis
Multiple myeloma and AL amyloidosis are both caused by the expansion of monoclonal plasma cells and each involve dysproteinemia. Each disease state can occur independently, but in rare instances AL amyloidosis occursin patients diagnosed with multiple myeloma.
D.All of the above
Multiple myeloma-associated AL amyloidosis can affect any organ system, including myocardia, renal, bone, dermal and subcutaneous tissues.
C.Poor survival
A recent review of 32 published cases suggested a higher prevalence of concurrent cutaneous AL amyloidosis and multiple myeloma in women (66% of cases). Nineteen of the 32 patients were white. Most (64%) of the patients died within 6 months of diagnosis.
B.56%
Most (56%) of the 32 published cases of concurrent AL amyloidosis and multiple myeloma reviewed presented as hemorrhagic bullous lesions. Another 25% presented as purpura/ecchymosis.
C.Cardiac failure
AL amyloidosis is commonly classified to reflect whether cardiac, renal, gastrointestinal, pulmonary, or other tissues are primarily affected by amyloid depositions. Symptoms vary depending on involved organ systems but the most common cause of death for these patients is cardiac failure.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.